On Dec. 22, the U.S. Food and Drug Administration (FDA) updated the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response.
Read more via Fda.gov.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
